Get the Stockscreener App
35.20
2.49%
-0.90
After Hours:
35.75
0.55
+1.56%
Grail Inc stock is traded at $35.20, with a volume of 878.21K.
It is down -2.49% in the last 24 hours and up +41.37% over the past month.
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
See More
Previous Close:
$36.10
Open:
$36.3
24h Volume:
878.21K
Relative Volume:
0.60
Market Cap:
$1.26B
Revenue:
$117.67M
Net Income/Loss:
$-1.88B
P/E Ratio:
-0.5815
EPS:
-60.5369
Net Cash Flow:
$-621.36M
1W Performance:
-1.61%
1M Performance:
+41.37%
6M Performance:
+143.09%
1Y Performance:
+0.00%
1-Day Range:
$34.99
$37.23
1-Week Range:
$31.39
$37.32
52-Week Range:
$12.33
$63.99
Grail Inc Stock (GRAL) Company Profile
Name
Grail Inc
Sector
Industry
Phone
(833) 694-2553
Address
1525 O'BRIEN DRIVE, MENLO PARK
Compare GRAL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRAL
Grail Inc
|
35.20 | 1.26B | 117.67M | -1.88B | -621.36M | -60.54 |
|
TMO
Thermo Fisher Scientific Inc
|
403.13 | 159.89B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.73 | 142.45B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
491.70 | 37.95B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
106.93 | 30.97B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
148.99 | 26.72B | 15.50B | 1.33B | 2.16B | 7.34 |
Grail Inc Stock (GRAL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Initiated | Canaccord Genuity | Buy |
| Nov-27-24 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Oct-17-24 | Initiated | Guggenheim | Neutral |
Grail Inc Stock (GRAL) Latest News
SEC ends probe of Illumina’s Grail acquisition - MedTech Dive
Illumina confirms SEC has closed investigation into $8B Grail deal - Endpoints News
Grail’s CFO Aaron Freidin sells $1.4 million in stock By Investing.com - Investing.com Nigeria
Grail’s CFO Aaron Freidin sells $1.4 million in stock - Investing.com Australia
Lobbying Update: $500,000 of GRAIL INC. (FORMERLY GRAIL LLC) lobbying was just disclosed - Nasdaq
Why GRAIL, Inc. (GRAL) is Surging in 2025 - Insider Monkey
GRAIL to Announce First Quarter 2025 Financial Results - The Victoria Advocate
CEO Sam Hazen on where technology will be HCA's 'holy grail' - The Business Journals
GRAIL to Present New Data on Galleri® and its Methylation Platform at American Association for Cancer Research (AACR) Annual Meeting - PR Newswire
Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook Confidence - Benzinga
Opinion | The FTC vs. the War on Cancer - WSJ
This Cancer Test Could Become Routine—and a Big Seller, Says Analyst - Barron's
Canaccord starts Grail with a Buy, sees ‘solid upside’ - TipRanks
Canaccord sets $32 target on GRAIL stock with buy rating By Investing.com - Investing.com Nigeria
Canaccord Genuity Initiates GRAIL at Buy With $32 Price Target - marketscreener.com
Canaccord sets $32 target on GRAIL stock with buy rating - Investing.com
GRAIL, Inc. (GRAL): A Bull Case Theory - MSN
Form DEF 14A GRAIL, Inc. For: May 29 - StreetInsider
GRAIL's Galleri Progresses While Back In Accumulation Levels - Seeking Alpha
AI-Powered Studio GRAiL Launched By Davide Bianca & Jeff Krelitz - Deadline
How Does GRAIL Benefit From The Proposed MCED Legislation? (NASDAQ:GRAL) - Seeking Alpha
Multi-Cancer Early Detection Market Critical Analysis with Expert Opinion| GRAIL, Natera, Elypta - openPR.com
Jim Cramer Likes GRAIL, Inc. (GRAL) Despite Losses – Great Science, Risky Bet! - Yahoo Finance
Illumina to buy Jeff Bezos-backed cancer testing firm Grail in $8 billion deal - MarketScreener
A Sydney company’s laser focus on energy’s holy grail - @AuManufacturing
Opinion | One ‘Monopoly’ That Could Save Your Life - The Wall Street Journal
Is GRAIL Stock About to Skyrocket? - timothysykes.com
GRAIL Careers, Perks + Culture - Built In
Debate Over Multi-Cancer Screening Tests Shifts Pending Grail Randomized Trial Results - GenomeWeb
FDA approval remains Holy Grail for Aussie biotechs - NT News
Biocurious: FDA approval remains the Holy Grail for ASX life science stocks - Stockhead
Grail price target raised to $20 from $16 at Morgan Stanley - TipRanks
Have Insiders Sold GRAIL Shares Recently? - Simply Wall St
Jim Cramer On Netflix, Inc. (NFLX) – Subscription Is the Holy Grail—Netflix Is Doing Very Well! - Insider Monkey
Illumina Wins Court Fight With EU Over $7 Billion Grail Deal - MSN
Grail president Joshua Ofman sells $65,800 in common stock By Investing.com - Investing.com Australia
Grail CEO Robert Ragusa sells $237,976 in stock By Investing.com - Investing.com Canada
Grail CEO Robert Ragusa sells $237,976 in stock - Investing.com India
Grail president Joshua Ofman sells $65,800 in common stock - Investing.com
Oppenheimer & Co. Inc. Invests $190,000 in Grail, Inc. (NASDAQ:GRAL) - Defense World
Rhumbline Advisers Makes New Investment in Grail, Inc. (NASDAQ:GRAL) - Defense World
New York State Common Retirement Fund Makes New $59,000 Investment in Grail, Inc. (NASDAQ:GRAL) - Defense World
Grail’s Stock Surge: An Eye on Future Moves - timothysykes.com
GRALGrail Inc Latest Stock News & Market Updates - StockTitan
Is GRAIL, Inc. (GRAL) Among Jeff Bezos’ Investments in 2025? - Yahoo Finance
Grail Inc Stock (GRAL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.60%
1.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):